Expression of Cell Cycle Proteins in 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced Mouse Lung Tumors

References

• Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Sherr C J. Mammalian G1 cyclins. Cell. 1993; 73: 1059–1065
   PubMed Web of Science ®Google Scholar
• Sherr C J, Roberts J M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9: 1149–1163
   PubMed Web of Science ®Google Scholar
• Weinberg R A. The retinoblastoma protein and cell cycle control. Cell. 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Sherr C J. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Schauer I E, Siriwardana S, Langan T A, Sclafani R A. Cyclin D1 overexpression versus retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA. 1994; 91: 7827–7831
   PubMed Web of Science ®Google Scholar
• Shapiro G I, Edwards C K, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Mate J L, Ariza A, Aracil C, et al. Cyclin D1 overexpression in non-small cell lung carcinoma correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol. 1996; 180: 395–399
   PubMed Web of Science ®Google Scholar
• Betticher D C, Heighway J, Hasleton P S, et al. Prognostic significance of CCND1 (cyclin D1) over-expression in primary resected non-small-cell lung cancer. Br J Cancer. 1996; 73: 294–300
   PubMed Web of Science ®Google Scholar
• Yang W -I, Chung K -Y, Shin D -H, Kim Y -B. Cyclin D1 protein expression in lung cancer. Yonsei Med J. 1996; 37: 142–150
   PubMedGoogle Scholar
• Said T K, Luo L, Medina D. Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclin D1 and D2 binding to cdk4. Carcinogenesis. 1995; 16: 2507–2513
   PubMed Web of Science ®Google Scholar
• Wang Q -S, Sabourin C LK, Wang H, Stoner G D. Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis. 1996; 17: 1583–1588
   PubMed Web of Science ®Google Scholar
• Youssef E M, Hasuma T, Morishima Y, et al. Overexpression of cyclin D1 in rat esophageal carcinogenesis model. Jpn J Cancer Res. 1997; 88: 18–25
   PubMedGoogle Scholar
• Bianchi A B, Fischer S M, Robles A I, Rinchik E M, Conti C J. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene. 1993; 8: 1127–1133
   PubMedGoogle Scholar
• Robles A I, Conti C J. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis. 1995; 16: 781–786
   PubMedGoogle Scholar
• He J, Olson J, James C D. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 1995; 55: 4833–4836
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Yoshimoto T, Skiya T. Homozyous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene. 1995; 11: 2145–2149
   PubMed Web of Science ®Google Scholar
• Rollbroker B, Waha A, Louis D N, Wiestler O D, von Deimling A. Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol. 1996; 92: 70–74
   PubMed Web of Science ®Google Scholar
• Khatib Z A, Matsushime H, Valentine M, Shapiro D N, Sherr C J, Look A T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993; 53: 5535–5541
   PubMed Web of Science ®Google Scholar
• Wang Y L, Uhara H, Yamazaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol. 1996; 134: 269–275
   PubMed Web of Science ®Google Scholar
• Zhang T, Nanney L B, Luongo C, et al. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997; 57: 169–175
   PubMed Web of Science ®Google Scholar
• Sgambato A, Han EK -H, Zhang Y -J, Moon R C, Santella R M, Weinstein I B. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced mammary tumors. Carcinogenesis. 1995; 16: 2193–2198
   PubMed Web of Science ®Google Scholar
• Otterson G A, Kratzke R A, Coxon A, Kim Y W, Kaye F J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 1994; 9: 3375–3378
   PubMed Web of Science ®Google Scholar
• Shapiro G I, Edwards C K, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Kelley M J, Nakagawa K, Steinberg S M, Mulshine J L, Kamb A, Johnson B E. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst. 1995; 87: 756–761
   PubMedGoogle Scholar
• Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996; 65: 442–445
   PubMed Web of Science ®Google Scholar
• Kratzke R A, Greatens T M, Rubins J B, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996; 56: 3415–3420
   PubMed Web of Science ®Google Scholar
• Kinoshita I, Dosaka-Akita H, Mishina T, et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 1996; 56: 5557–5562
   PubMed Web of Science ®Google Scholar
• Harbour J W, Lai S -L, Whang-Peng J, Gazdar A F, Minna J D, Kaye F J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241: 353–357
   PubMed Web of Science ®Google Scholar
• Yokata J, Akiyama T, Fung Y -KT, et al. Altered expression of the retinoblastoma (Rb) gene in small-cell carcinoma of the lung. Oncogene. 1988; 3: 471–475
   PubMed Web of Science ®Google Scholar
• Hensel C H, Hsieh C -L, Gazdar A F, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 1990; 50: 3067–3072
   PubMed Web of Science ®Google Scholar
• Xu H -J, Hu S -X, Cagle P T, Moore G E, Benedict W F. Absence of retinoblastoma prote in expression in primary non-small cell lung carcinomas. Cancer Res. 1991; 51: 2735–2739
   PubMed Web of Science ®Google Scholar
• Xu H -J, Quinlan D C, Davidson A G, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994; 86: 695–699
   PubMed Web of Science ®Google Scholar
• Reissmann P T, Koga H, Takahashi R, et al, The Lung Cancer Study Group. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene. 1993; 8: 1913–1919
   PubMed Web of Science ®Google Scholar
• Shimizu E, Coxon A, Otterson G A, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994; 9: 2441–2448
   PubMed Web of Science ®Google Scholar
• Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 1995; 55: 514–517
   PubMed Web of Science ®Google Scholar
• Okamoto A, Hussain S P, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/ MTS2 and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995; 55: 1448–1451
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Conrad N K, Williams J P, Johnson B E, Kelley M J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 1995; 11: 1843–1851
   PubMed Web of Science ®Google Scholar
• Malkinson A M. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res (Suppl). 1992; 52: 2670s–2676s
   PubMed Web of Science ®Google Scholar
• Hecht S S, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988; 9: 875–884
   PubMed Web of Science ®Google Scholar
• Stoner G D, Adam-Rodwell G, Morse M A. Lung tumors in strain A mice: application for studies in cancer chemoprevention. J Cell Biochem. 1993; 17F95–103
   Google Scholar
• Shimkin M B, Stoner G D. Lung tumors in mice: Application to carcinogenesis bioassay. Adv Cancer Res. 1975; 21: 1–58
   PubMedGoogle Scholar
• Belinsky S A, Devereux T R, Maronpot R R, Stoner G D, Anderson M W. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res. 1989; 49: 5305–5311
   PubMed Web of Science ®Google Scholar
• You M, Candrian U, Maronpot R R, Stoner G D, Anderson M W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA. 1989; 86: 3070–3074
   PubMed Web of Science ®Google Scholar
• Devereux T R, Anderson M W, Belinsky S A. Role of ras protooncogene activation in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse. Carcinogenesis. 1991; 12: 299–303
   PubMed Web of Science ®Google Scholar
• You M, Wang Y L, Stoner G D, et al. Parental bias of K-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci USA. 1992; 89: 5804–5808
   PubMed Web of Science ®Google Scholar
• Chen B, Liu L, Castonguay A, Maronpot R R, Anderson M W, You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4- (methylnitrosamino)-1- (3-pyridyl) -1-butanone induced mouse lung tumors. Carcinogenesis. 1993; 14: 1603–1608
   PubMed Web of Science ®Google Scholar
• Matzinger S A, Crist K A, Stoner G D, et al. K-ras mutations in lung tumors from A/J and A/JXTSG-p53 F1 mice treated with 4- (methylnitrosamino)-1- (3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis. 1995; 16: 2487–2492
   PubMed Web of Science ®Google Scholar
• Goodrow T L, Storer R D, Leander K R, Prahalada S R, van Zwieten M J, Bradley M O. Murine p53 intron sequences 5–8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol Carcinog. 1992; 5: 9–15
   PubMed Web of Science ®Google Scholar
• Horio Y, Chen A, Rice P, Roth J A, Malkinson A M, Schrump D S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996; 17: 217–223
   PubMed Web of Science ®Google Scholar
• Herzog C R, Soloff E V, McDoniels A L, et al. Homozygous codeletion and differential decreased expression of p15INK4b p16INK4a-α and p16INKa-β in mouse lung tumor cells. Oncogene. 1996; 13: 1885–1892
   PubMed Web of Science ®Google Scholar
• Belinsky S A, Swafford D S, Middleton S K, Kennedy C H, Tesfaigzi J. Deletion and differential expression of p16INK4a in mouse lung tumors. Carcinogenesis. 1997; 18: 115–120
   PubMed Web of Science ®Google Scholar
• Herzog C R, Chen B, Wang Y, Schut H AJ, You M. Loss of heterozygosity on chromosomes 1, 11, 12, and 14 in hybrid mouse lung adenocarcinomas. Mol Carcinog. 1996; 16: 83–90
   PubMed Web of Science ®Google Scholar
• Re F C, Manenti G, Borrello M G, et al. Multiple molecular alterations in mouse lung tumors. Mol Carcinog. 1992; 5: 155–160
   PubMed Web of Science ®Google Scholar
• Foley J F, Anderson M W, Stoner G D, Gaul B W, Hardisty J F, Maronpot R R. Proliferative lesions of the mouse lung: progression studies in strain A mice. Exp Lung Res. 1991; 17: 157–168
   PubMed Web of Science ®Google Scholar
• Murphy L D, Herzog C E, Rudick J B, Fojo A T, Bates S E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990; 29: 10351–10356
   PubMed Web of Science ®Google Scholar
• Quelle D E, Ashmun R A, Hannon G J, et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene. 1995; 11: 635–645
   PubMed Web of Science ®Google Scholar
• Konecki D S, Brennand J, Fuscoe J C, Caskey C T, Chinault A C. Hypoxanthine-guanine phosphoribosyltransferase genes of mouse and Chinese hamster: construction and sequence analysis of cDNA recombinants. Nucleic Acids Res. 1982; 10: 6763–6775
   PubMed Web of Science ®Google Scholar
• Nakayama H, Yokoi H, Fujita J. Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 1992; 20: 4939
   PubMed Web of Science ®Google Scholar
• Hongyo T, Buzard G S, Calvert R J, Weghorst C M. Cold SSCP: a simple, rapid and non-radioactive method for optimized single strand conformation polymorphism analyses. Nucleic Acids Res. 1993; 16: 3637–3642
   Google Scholar
• Jiang W, Kahn S M, Zhou P, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993; 8: 3447–3457
   PubMed Web of Science ®Google Scholar
• Wang T C, Cardiff R D, Zukerberg L, Lees E, Arnold A, Schmidt E V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669–671
   PubMed Web of Science ®Google Scholar
• Schrump D S, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 1996; 3: 131–135
   PubMed Web of Science ®Google Scholar
• Zhou P, Jiang W, Shang Y -J, et al. Antisense of cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 1995; 11: 571–580
   PubMed Web of Science ®Google Scholar
• Nadir A, Doki Y, Han EK -H, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997; 57: 1569–1574
   PubMed Web of Science ®Google Scholar
• Filmus J, Robles A I, Shi W, Wong M J, Colomobo L L, Conti C J. Induction of cyclin D1 over-expression by activated ras. Oncogene. 1994; 9: 3627–3633
   PubMed Web of Science ®Google Scholar
• Bodrug S E, Warner B J, Bath M L, Lindeman G J, Harris A W, Adams J M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994; 13: 2124–2130
   PubMed Web of Science ®Google Scholar
• Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986; 322: 78–80
   PubMed Web of Science ®Google Scholar
• Roop D R, Lowy D R, Tambourin P E, et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986; 323: 822–824
   PubMed Web of Science ®Google Scholar
• Mitsunaga S I, Zhang S Y, Ruggeri B A, et al. Positive immunohistochemical staining of p53 and cyclin D1 in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a]pyrene. Carcinogenesis. 1995; 16: 1629–1635
   PubMed Web of Science ®Google Scholar
• Ruggeri B A, Bauer B, Zhang S -Y, Klein-Szanto A JP. Murine squamous cell carcinoma cell lines produced by a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cylI/cyclin D1 abnormalities. Carcinogenesis. 1994; 15: 1613–1619
   PubMed Web of Science ®Google Scholar
• DiGiovanni J, Beltran L, Rupp A, Harvey R G, Gill R D. Further analysis of c-Ha-ras mutations in papillomas initiated by several polycyclic aromatic hydrocarbons and papillomas from uninitiated, promoter-treated skin in SENCAR mice. Mol Carcinog. 1993; 8: 272–279
   PubMed Web of Science ®Google Scholar
• Okamoto A, Demetrick D J, Spillare E A, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1991; 91: 11045–11049
   Google Scholar
• Spillare E A, Okamoto A, Hagiwara K, et al. Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4. Mol Carcinog. 1996; 16: 53–60
   PubMed Web of Science ®Google Scholar
• Herzog C R, Wiseman R W, You M. Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer Res. 1994; 54: 4007–4010
   PubMed Web of Science ®Google Scholar
• Hegi M E, Devereux T R, Dietrich W F, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994; 54: 6257–6264
   PubMed Web of Science ®Google Scholar
• Merlo A, Herman J G, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995; 1: 686–692
   PubMed Web of Science ®Google Scholar
• Herman J G, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zulueta M, Bender C M, Yang A S, et al. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995; 55: 4531–4535
   PubMed Web of Science ®Google Scholar
• Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996; 56: 3875–3878
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yandell D W. How sensitive is PCR-SSCP?. Hum Mutat. 1993; 2: 338–346
   PubMed Web of Science ®Google Scholar